Protocol Ledger

NCT05736965 · Phase II · RECRUITING

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Interventional Phase II clinical trial protocol NCT05736965 sponsored by Shanghai Tong Ren Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-20 Enrollment: 58 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05736965
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05736965
Protocol FieldVerified Registry Value
NCT IdentifierNCT05736965
Consolidated Lead SponsorShanghai Tong Ren Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment58 participants (ESTIMATED)
Registered Start Date2023-02-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI